Literature DB >> 19122133

Obsessive-compulsive disorder with mitochondrial disease.

Cameron J Lacey1, Michael R Salzberg.   

Abstract

BACKGROUND: Mitochondrial diseases are among the most common genetic disorders, and they have been associated with several psychiatric syndromes.
METHOD: The authors present two cases of obsessive-compulsive disorder (OCD) occurring in patients with MELAS (the A3243G mutation).
RESULTS: Their clinical course and response to standard OCD treatment strategies was poor. DISCUSSION: Possible mechanisms for OCD symptoms are suggested by animal models and neuropathological findings. It remains unclear whether different types of mitochondrial disorders are associated with particular neuropsychiatric symptoms. Psychiatric symptoms may predate the diagnosis of mitochondrial disorder; thus, psychiatrists should consider mitochondrial disorders in the presence of common physical signs that are typically associated with these disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19122133     DOI: 10.1176/appi.psy.49.6.540

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  3 in total

1.  Psychiatric symptoms of patients with primary mitochondrial DNA disorders.

Authors:  Gabriella Inczedy-Farkas; Viktoria Remenyi; Aniko Gal; Zsofia Varga; Petra Balla; Agnes Udvardy-Meszaros; Benjamin Bereznai; Maria Judit Molnar
Journal:  Behav Brain Funct       Date:  2012-02-13       Impact factor: 3.759

Review 2.  Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review.

Authors:  Chiara Brusa; Giulio Gadaleta; Rossella D'Alessandro; Guido Urbano; Martina Vacchetti; Chiara Davico; Benedetto Vitiello; Federica S Ricci; Tiziana E Mongini
Journal:  Brain Sci       Date:  2022-01-28

3.  Alterations of cellular aging markers in obsessive- compulsive disorder: mitochondrial DNA copy number and telomere length.

Authors:  Jee In Kang; Chun Il Park; Jue Lin; Shin Tae Kim; Hae Won Kim; Se Joo Kim
Journal:  J Psychiatry Neurosci       Date:  2021-07-22       Impact factor: 6.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.